INBX Inhibrx Biosciences, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$99.29

Period return

+17.04 (+20.72%)

Volume

261.2K

2026-06-01O $104 H $105.09 L $96.75 C $99.29MA5 $103.43MA20 $114.51MA60 $92.65MA120 $85.7

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 04. 08.MediumBUY2 months ago
Stifel: Buy
US analyst rating / recommendation change.
2025. 08. 22.LowHOLD9 months ago
JMP Securities: Market Perform
US analyst rating / recommendation change.
2025. 05. 15.LowHOLDlast year
JMP Securities: Market Perform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $277.5 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Sector: Healthcare
Industry: Biotechnology
HQ: La Jolla, CA, United States
Fiscal year end: —
Employees: 109
IPO date: —

View details →